![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: XKR8 |
Gene summary for XKR8 |
![]() |
Gene information | Species | Human | Gene symbol | XKR8 | Gene ID | 55113 |
Gene name | XK related 8 | |
Gene Alias | XRG8 | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0001776 | UniProtAcc | Q9H6D3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55113 | XKR8 | HCC1_Meng | Human | Liver | HCC | 1.02e-35 | 3.99e-02 | 0.0246 |
55113 | XKR8 | HCC2 | Human | Liver | HCC | 1.57e-02 | 2.11e+00 | 0.5341 |
55113 | XKR8 | S014 | Human | Liver | HCC | 3.66e-10 | 4.05e-01 | 0.2254 |
55113 | XKR8 | S015 | Human | Liver | HCC | 3.95e-10 | 6.57e-01 | 0.2375 |
55113 | XKR8 | S016 | Human | Liver | HCC | 3.15e-09 | 3.82e-01 | 0.2243 |
55113 | XKR8 | S029 | Human | Liver | HCC | 8.99e-04 | 2.29e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000226222 | Liver | HCC | myeloid cell homeostasis | 93/7958 | 157/18723 | 1.67e-05 | 1.81e-04 | 93 |
GO:004887222 | Liver | HCC | homeostasis of number of cells | 147/7958 | 272/18723 | 7.48e-05 | 6.70e-04 | 147 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
XKR8 | SNV | Missense_Mutation | c.923N>G | p.Ser308Cys | p.S308C | Q9H6D3 | protein_coding | tolerated(0.08) | possibly_damaging(0.556) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
XKR8 | SNV | Missense_Mutation | novel | c.778C>G | p.Leu260Val | p.L260V | Q9H6D3 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
XKR8 | SNV | Missense_Mutation | novel | c.902N>T | p.Ala301Val | p.A301V | Q9H6D3 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
XKR8 | SNV | Missense_Mutation | novel | c.1145N>C | p.Phe382Ser | p.F382S | Q9H6D3 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
XKR8 | SNV | Missense_Mutation | c.652N>A | p.Val218Met | p.V218M | Q9H6D3 | protein_coding | tolerated(0.07) | possibly_damaging(0.837) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
XKR8 | SNV | Missense_Mutation | novel | c.557G>A | p.Arg186His | p.R186H | Q9H6D3 | protein_coding | deleterious(0.01) | possibly_damaging(0.721) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
XKR8 | SNV | Missense_Mutation | novel | c.1137N>T | p.Gln379His | p.Q379H | Q9H6D3 | protein_coding | deleterious(0.03) | benign(0.275) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
XKR8 | SNV | Missense_Mutation | c.590T>C | p.Leu197Pro | p.L197P | Q9H6D3 | protein_coding | tolerated(0.26) | benign(0.007) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
XKR8 | SNV | Missense_Mutation | rs145087283 | c.601N>A | p.Val201Met | p.V201M | Q9H6D3 | protein_coding | deleterious(0.03) | probably_damaging(0.913) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
XKR8 | SNV | Missense_Mutation | rs554587970 | c.1073N>A | p.Arg358Gln | p.R358Q | Q9H6D3 | protein_coding | tolerated(0.22) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |